ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Neurology

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

7,911Medicare Part D Prescriptions Filled, Including Refills

Rank: 1 out of 697

$1.33M Total Retail Price of All Prescriptions

Rank: 25 out of 697

750 Patients Receiving at Least One Drug in Part D
83%Patients 65 Years and Older
87% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New York
Lower avg

Schedule Two
Controlled Substances

2% of this provider’s 750 patients filled at least one prescription for a schedule two drug, compared to an average of 3%.

Schedule Three
Controlled Substances

6% of this provider’s 750 patients filled at least one prescription for a schedule three drug, compared to an average of 2%.

Risky Drugs to Seniors

1% of this provider’s 6,370 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

59% of this provider’s prescriptions were for brand-name drugs, compared to an average of 29%.

Prescription Price

$168 was the average price of a prescription from this provider, compared to $234 among peers.

Prescriptions per Patient

11 is the average number of prescriptions (including refills) per patient, compared to an average of 8.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New York
NAMENDA 449 408 1 5
CYMBALTA 378 296 2 17
GABAPENTIN 336 249 3 2
NORTRIPTYLINE HCL 328 280 4 24
ESCITALOPRAM OXALATE 300 291 5 44
LYRICA 275 199 6 10
DONEPEZIL HCL 256 243 7 3
EXELON 204 202 8 15
TRAMADOL HCL-ACETAMINOPHEN 195 148 9 89
AZILECT 182 164 10 16
PROPRANOLOL HCL 175 157 11 34
CARBIDOPA-LEVODOPA 173 137 12 1
LEXAPRO 159 145 13 88
TOPIRAMATE 159 69 13 7
LIDODERM 149 99 15 58
CARBIDOPA-LEVODOPA-ENTACAPONE 144 138 10 16 69
TRAZODONE HCL 127 101 17 38
SERTRALINE HCL 118 98 18 23
STALEVO 100 106 105 10 19 116
PRIMIDONE 105 102 20 11
KEPPRA XR 104 96 10 21 92
QUETIAPINE FUMARATE 100 90 22 30
STALEVO 150 89 71 10 23 151
VOLTAREN 87 67 24 72
MAXALT MLT 87 48 10 24 102
LAMICTAL XR 82 11 26 54
STALEVO 200 82 82 10 26 184
OXCARBAZEPINE 74 65 28 25
TRAMADOL HCL 73 49 29 33
ARICEPT 68 68 30 51
SEROQUEL 63 60 31 74
VENLAFAXINE HCL ER 62 40 32 47
ZOLPIDEM TARTRATE 62 45 32 26
SOLARAZE 62 58 32 204
PLAVIX 62 62 32 77
HYDROCODONE-ACETAMINOPHEN 61 29 S3 36 8
PRAMIPEXOLE DIHYDROCHLORIDE 60 44 37 19
SAVELLA 58 0 38 211
STALEVO 125 58 58 10 38 211
GRALISE 56 45 40 215
STALEVO 50 56 47 10 40 158
ZELAPAR 54 51 10 42 224
MIRAPEX ER 52 37 43 121
CITALOPRAM HBR 50 50 44 28
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 22, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.